Semax and Selank: what the studies found

Reviewed 38 sourcesPublished by PepVault

Semax and Selank are Russian nasal-drop peptides with no FDA approval. Every PubMed human study of each, with its size, its design and what it measured.

A man in a mustard sweater playing chess at a sunny table
Last reviewed
Sources
38
Questions
10
Compounds
2

The short answer

Semax and Selank are short lab-made peptides, seven amino acids each, sold in Russia as nasal drops: Semax since 1994, on prescription, for stroke and memory problems, and Selank since 2009, without one, for anxiety. Neither is approved by the FDA or in the EU. Their human record is a set of small Russian studies; the only placebo-controlled ones are brain-scan studies of 24 and 52 healthy volunteers.

Every number checked at its primary source · · 38 sources · How we research

Evidence: Human evidence: small Russian studies, most without a placebo group and published in Russian; the only placebo-controlled studies measured brain scans in healthy volunteers. How they work comes from rats, mice and lab dishes.

A man in a mustard sweater playing chess at a sunny table

What are Semax and Selank?

Both are heptapeptides, chains of seven amino acids, built in Moscow from a piece of a natural molecule plus the same three-amino-acid tail, Pro-Gly-Pro1. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) starts from ACTH 4-7, a fragment of the pituitary hormone ACTH35; its Russian label calls it an ACTH analogue with no hormonal activity5. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) starts from tuftsin, a four-amino-acid immune peptide, and the tail makes it resist the enzymes that cut peptides apart34.

In Russia, Semax is labelled for memory and thinking problems after vascular brain disease, stroke recovery, brain injury and optic nerve disease, and in children from age 7 for attention problems, including ADHD5. Selank is labelled for anxiety, neurasthenia (a state of lasting fatigue and irritability) and stress-related disorders6. Both come as drops for the nose; Semax needs a prescription and Selank does not56.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Add Semax or Selank from the PepVault library and it is set up as a nasal spray: each dose logs with one tap, with no injection site to record.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Are Semax and Selank approved anywhere?

Only in Russia. The registry records, as copied by Russia's RLS drug reference, give these dates:

ProductFirst registeredHolderCurrent record
Semax 0.1% nasal dropsDecember 20, 19943 (that record has expired)Institute of Molecular Genetics, Russian Academy of Sciences; Peptogen today5Re-registered March 26, 20255
Semax 1% nasal dropsDecember 29, 20114PeptogenNumber Р N000812/01, no end date4
Selank 0.15% nasal drops2009 (number ЛСР-003338/09)6PeptogenRe-registered July 15, 20256

In the United States, Drugs@FDA lists no application for either one29. In July 2026, FDA's staff took Semax to its Pharmacy Compounding Advisory Committee and recommended against adding it to the list of substances pharmacies may compound, citing missing quality data, too little safety information and too little evidence that it works2. The committee met on July 2426, and on October 30, 2026 HHS published a draft policy: until a final rule decides, it does not intend to act against pharmacies that compound Semax, as a nasal product on a prescription3738. That is not an approval, and the policy binds no one37. Neither peptide appears in the European Medicines Agency's register of authorised medicines27.

How does a nasal peptide reach the brain?

The label route is intranasal: drops into each nostril, absorbed through the lining of the nose56. In rats given a tritium-tagged Semax in the nose, 0.093% of the dose per gram of brain tissue was in the brain two minutes later, and the peptide broke down fast, mostly into its Pro-Gly-Pro tail24. In mice, Selank given in the nose and Selank injected into the belly changed different brain receptors, so the route changed the effect28.

Species note: both findings come from rodents. FDA found no study of how Semax is absorbed or cleared in people, by any route2.

Add Semax or Selank from the PepVault library and it is set up as a nasal spray: each dose logs with one tap, with no injection site to record. Log it in PepVault

What did the Semax studies in people measure?

These are the human studies of Semax indexed in PubMed with a size in the abstract, or in FDA's 2026 review where the abstract gives none2. Most are in Russian with an English abstract.

StudyWhoSizeDesignWhat it found
Gusev 19977Acute ischemic stroke30, against 80 on usual careAdded to usual care, no placeboFaster recovery of motor and other deficits
Gusev 20058Reduced blood flow to the brain187Design not given in the abstractClinical improvement, fewer strokes and mini-strokes, few side effects
Gusev 20189After ischemic stroke, in rehab110With and without Semax, 5 monthsBlood BDNF rose and stayed high; daily function (Barthel score) improved faster
Serdiuk 200710Motor neuron disease27Open-label, no controlNo change in disease course; quality of life better, best at day 10
Alekseeva 199911Lasting brain damage from oxygen loss73No control describedHelped memory problems; seizure-like EEG bursts in some
Ivanikov 200212Peptic ulcers that would not heal322Added to ulcer drugs, against ulcer drugs aloneHealed by day 14: 89.5% against 30.8%
Nazarova 201313Diabetic eye disease114Three groups, two with SemaxBetter vision tests with Semax
Dontsova 201536Psoriasis with metabolic syndrome118 (60 Semax, 58 usual care)Added to usual treatment, 10 daysBlood cholesterol and triglycerides fell; no change on usual care alone
Koroleva 199616Migraine and facial nerve pain372One dose, no controlMigraine pain stopped in 4 of 122
Lebedeva 201814Healthy volunteers24 (14 Semax, 10 placebo)One nasal dose against placeboA resting brain network on MRI grew in its front part
Panikratova 202015Healthy volunteers52One dose of Semax, Selank or placeboChanged connections of the amygdala, an emotion region

Other papers in optic nerve disease, glaucoma and eye surgery give no size in their abstracts or pair Semax with physiotherapy, so they cannot show what Semax did alone303132. FDA also counted 451 children, with depression or with tics, in two studies where Semax was given with other treatments; it found the full reports unavailable2.

What did the Selank studies in people measure?

Selank's human record in PubMed is four clinical papers and the shared brain-scan study. All compare it with a benzodiazepine (a standard anti-anxiety drug) or with nothing; none has a placebo group.

StudyWhoSizeDesignWhat it found
Zozulia 200817Generalized anxiety disorder and neurasthenia62 (30 Selank, 32 medazepam)Against medazepamSimilar anxiety relief; Selank also eased fatigue
Medvedev 201418Anxiety and somatoform disorders60Against phenazepamClear anxiety relief and a mild effect on thinking, lasting a week after the last dose
Medvedev 201519Anxiety disorders70 (30 phenazepam alone, 40 with Selank)Added to phenazepamPhenazepam worked sooner, with fewer of its side effects such as sleepiness and memory lapses
Uchakina 200820Anxiety with fatigueNot given14 days, blood testsShifts in immune signalling molecules (cytokines)
Panikratova 202015Healthy volunteers52One dose against placeboChanged connections of the amygdala

How strong is the evidence for Semax and Selank?

Thin, and the tables show why. Across both peptides, the only studies with a placebo group are the two brain-scan studies, and they measured scans in healthy people over 20 minutes, not symptoms1415. No abstract above says the patients were randomized or that anyone was blinded. The largest studies, of 187, 118 and 114 people, do not say how patients were put into groups83613.

Most of the Selank papers and several Semax papers list N. F. Myasoedov, of the Institute of Molecular Genetics that holds Semax's first registration, among their authors371719. ClinicalTrials.gov holds no registered trial of either peptide33. When FDA reviewed Semax in 2026, it set aside the Russian-language stroke papers because no English translation was supplied, and judged the evidence insufficient for stroke, migraine and facial nerve pain2. A 2021 US review called Selank a poorly studied Russian drug25.

What do the animal studies show?

Most of what is said about how these peptides work comes from rodents. In rats, one dose of Semax raised BDNF, a growth signal for nerve cells, by up to 1.4-fold in the hippocampus, the memory region21. In rats, Selank changed the activity of 45 of 84 genes tied to nerve signalling within an hour, in a pattern that tracked GABA, the brain's main calming signal23. In human blood serum in a lab dish, both slowed the enzymes that break down enkephalins, the body's own pain-and-mood peptides1.

Species note: the BDNF and gene results are from rats; the enzyme result is from serum in a dish, not from people taking the drug.

Is Semax a stimulant?

Not in the usual sense: on its own, Semax did not change dopamine levels in rodents22. Given 20 minutes before amphetamine, though, it sharply increased amphetamine's dopamine release and activity in rodents22, a finding FDA singled out as a concern2. Its Russian label files it under "other psychostimulants and nootropics" (ATC code N06BX) and lists anxiety disorders and acute mental states among the reasons not to use it5.

Is Selank or Semax better?

They were built for different jobs, so the studies cannot rank them. Semax's patients had strokes, brain injuries or eye disease7913; Selank's had anxiety1718. The one study that gave both, to healthy volunteers, found shared and separate effects on amygdala connections, measured on a scan rather than in how people felt15. No study has tested them taken together.

Commonly reported: of 31 people whose open write-ups on Semax we counted, 22 described an effect they wanted, most often clearer, quicker thinking; 4 described one they did not, such as the effect fading, worse sleep or irritability. Of 22 people writing about Selank, 19 described a wanted effect, most often feeling calmer.

What side effects do the labels list?

Semax's Russian label lists mild irritation of the nose lining with long use5. Selank's lists allergic reactions in people sensitive to it and an unpleasant taste when drops run into the throat6. Both labels rule out pregnancy and breastfeeding; Selank's also rules out anyone under 18, and Semax's anyone under 756. Most of the Semax studies FDA reviewed did not report side effects at all2.

Give each dose a time and switch on its reminder, and PepVault sends a push shortly after that time if it is still unlogged; a note on each log keeps what you noticed beside the dose. Set reminders in PepVault

When to get help Semax's label lists a history of seizures as a reason not to use it, and FDA raised a bleeding question from clotting data in rats, so anyone with seizures or on a blood thinner should talk to a clinician first2511.

Track it in the app

Sources

  1. Kost NV et al. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001. PubMed 11443939
  2. FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: FDA briefing document for Semax-related bulk drug substances (evaluation dated May 11, 2026). fda.gov
  3. RLS drug reference, registration record 94/294/10: Semax solution 0.1%, nasal drops, registered December 20, 1994 (holder: Institute of Molecular Genetics, Russian Academy of Sciences). rlsnet.ru
  4. RLS drug reference, registration record Р N000812/01: Semax 1% nasal drops, registered December 29, 2011 (holder: Peptogen). rlsnet.ru
  5. Vidal Russia. Semax 0.1% nasal drops: registration ЛП-№(009449)-(РГ-RU) of March 26, 2025, and the label (indications, contraindications, side effects). vidal.ru
  6. Vidal Russia. Selank 0.15% nasal drops: registration ЛП-№(010951)-(РГ-RU) of July 15, 2025 (previous ЛСР-003338/09), and the label. vidal.ru
  7. Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997. PubMed 11517472
  8. Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. PubMed 15792140
  9. Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29798983
  10. Serdiuk AV et al. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zh Nevrol Psikhiatr Im S S Korsakova. 2007. PubMed 18379501
  11. Alekseeva GV et al. Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziol Reanimatol. 1999. PubMed 10199046
  12. Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bull Exp Biol Med. 2002. PubMed 12459874
  13. Nazarova GA et al. The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy. Vopr Kurortol Fizioter Lech Fiz Kult. 2013. PubMed 24437205
  14. Lebedeva IS et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018. PubMed 30225715
  15. Panikratova YR et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020. PubMed 32342318
  16. Koroleva MV et al. Study of the analgesic effect of the semax preparation. Biull Eksp Biol Med. 1996. PubMed 8998343
  17. Zozulia AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18454096
  18. Medvedev VE et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PubMed 25176261
  19. Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PubMed 26356395
  20. Uchakina ON et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18577961
  21. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006. PubMed 16996037
  22. Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005. PubMed 16362768
  23. Volkova A et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016. PubMed 26924987
  24. Shevchenko KV et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim. 2006. PubMed 16523722
  25. Doyno CR, White CM. Sedative-hypnotic agents that impact gamma-aminobutyric acid receptors: focus on flunitrazepam, gamma-hydroxybutyric acid, phenibut, and selank. J Clin Pharmacol. 2021. PubMed 34396551
  26. FDA. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (meeting page). fda.gov
  27. European Medicines Agency. Medicines for human use: the full report of authorised medicines (searched November 20, 2026). ema.europa.eu
  28. Vasil'eva EV et al. Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksp Klin Farmakol. 2016. PubMed 29787664
  29. FDA. Drugs@FDA, searched through the openFDA drugsfda endpoint for semax and selank on November 20, 2026: no matches. api.fda.gov
  30. Polunin GS et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000. PubMed 10741256
  31. Kurysheva NI et al. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestn Oftalmol. 2001. PubMed 11569188
  32. Yusef Y et al. Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation. Vestn Oftalmol. 2026. PubMed 42885627
  33. ClinicalTrials.gov API v2, intervention searches for semax and selank on November 20, 2026: no trial of either peptide. clinicaltrials.gov
  34. Semenova TP et al. Experimental optimization of learning and memory processes by selank. Eksp Klin Farmakol. 2010. PubMed 20919548
  35. Filippenkov IB et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020. PubMed 32580520
  36. Dontsova EV. Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Eksp Klin Farmakol. 2015. PubMed 27051926
  37. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026. federalregister.gov
  38. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (draft, October 2026). hhs.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo